keyword
MENU ▼
Read by QxMD icon Read
search

ACOSOG

keyword
https://www.readbyqxmd.com/read/28453704/genomic-characterization-of-her2-positive-breast-cancer-and-response-to-neoadjuvant-trastuzumab-and-chemotherapy-results-from-the-acosog-z1041-alliance-trial
#1
R Lesurf, O L Griffith, M Griffith, J Hundal, L Trani, M A Watson, R Aft, M J Ellis, D Ota, V J Suman, F Meric-Bernstam, A M Leitch, J C Boughey, G Unzeitig, A U Buzdar, K K Hunt, E R Mardis
Background: HER2 (ERBB2) gene amplification and its corresponding overexpression are present in 15-30% of invasive breast cancers. While HER2-targeted agents are effective treatments, resistance remains a major cause of death. The American College of Surgeons Oncology Group Z1041 trial (NCT00513292) was designed to compare the pathologic complete response (pCR) rate of distinct regimens of neoadjuvant chemotherapy and trastuzumab, but ultimately identified no difference. Patients and methods: In supplement to tissues from 37 Z1041 cases, 11 similarly treated cases were obtained from a single institution study (NCT00353483)...
May 1, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28338482/axillary-ultrasound-fine-needle-aspiration-biopsy-is-there-a-role-in-the-post-z-0011-era
#2
Sarah E Pesek, Heather M King, Susan Koelliker, Christina Raker, David Edmonson, Don S Dizon, Jennifer Gass
OBJECTIVES: Axillary ultrasound with fine needle aspiration (AXUSFNA) in early-stage breast cancer has required reappraisal. ACOSOG Z-0011 and after mapping of the axilla: radiotherapy or surgery have shown that women with limited nodal disease at sentinel lymph node biopsy got no survival advantage with completion axillary node dissection. We hypothesize that AXUSFNA may be sufficiently accurate for staging for some patients and sentinel lymph node biopsy need not be performed. We define the false negative rate (FNR) of AXUSFNA in different subsets of patients...
March 23, 2017: American Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28327926/genomic-characterisation-of-her2-positive-breast-cancer-and-response-to-neoadjuvant-trastuzumab-and-chemotherapy-results-from-the-acosog-z1041-alliance-trial
#3
R Lesurf, O L Griffith, M Griffith, J Hundal, L Trani, M A Watson, R Aft, M J Ellis, D Ota, V J Suman, F Meric-Bernstam, A M Leitch, J C Boughey, G Unzeitig, A U Buzdar, K K Hunt, E R Mardis
Background: HER2 ( ERBB2 ) gene amplification and its corresponding overexpression are present in 15-30% of invasive breast cancers. While HER2-targeted agents are effective treatments, resistance remains a major cause of death. The American College of Surgeons Oncology Group Z1041 trial (NCT00513292) was designed to compare the pathologic complete response (pCR) rate of distinct regimens of neoadjuvant chemotherapy and trastuzumab, but ultimately identified no difference [1]. Patients and methods: In supplement to tissues from 37 Z1041 cases, 11 similarly treated cases were obtained from a single institution study (NCT00353483)...
February 21, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28295828/are-the-acosog-z0011-trial-findings-being-applied-to-breast-cancer-patients-undergoing-neoadjuvant-chemotherapy
#4
Olga Kantor, Catherine Pesce, Erik Liederbach, Chi-Hsiung Wang, David J Winchester, Katharine Yao
In 2010, the ACOSOG Z0011 trial showed equivalent survival and recurrence between sentinel lymph node biopsy (SLNB) alone versus axillary lymph node dissection (ALND) for those with a tumor positive sentinel node (SN). We examined national trends in axillary surgery following neoadjuvant chemotherapy (NAC) for clinically node positive disease in the years prior to and after the Z0011 trial publication. 12,063 women with cT1-4N1M0 invasive breast cancer who underwent NAC from 2006 to 2013 and had 1-3 positive nodes on pathology were selected from the National Cancer Data Base...
March 13, 2017: Breast Journal
https://www.readbyqxmd.com/read/28161935/can-we-skip-intraoperative-evaluation-of-sentinel-lymph-nodes-nomogram-predicting-involvement-of-three-or-more-axillary-lymph-nodes-before-breast-cancer-surgery
#5
Soo Kyung Ahn, Min Kyoon Kim, Jongjin Kim, Eunshin Lee, Tae-Kyung Yoo, Han-Byoel Lee, Young Joon Kang, Jisun Kim, Hyeong-Gon Moon, Jung Min Chang, Nariya Cho, Woo Kyung Moon, In Ae Park, Dong-Young Noh, Wonshik Han
Purpose: The American College of Surgeons Oncology Group (ACOSOG) Z0011 trial reported that complete dissection of axillary lymph nodes (ALNs) may not be warranted in women with clinical T1-T2 tumors and one or two involved ALNs who were undergoing lumpectomy plus radiation followed by systemic therapy. The present study was conducted to identify preoperative imaging predictors of ≥3 ALNs. Materials and Methods: The training set consisted of 1917 patients with clinical T1-T2 and node negative invasive breast cancer...
January 25, 2017: Cancer Research and Treatment: Official Journal of Korean Cancer Association
https://www.readbyqxmd.com/read/28139361/is-intraoperative-touch-imprint-cytology-indicated-in-the-surgical-treatment-of-early-breast-cancers
#6
Z Horváth, A Paszt, Z Simonka, M Látos, V Oláh, D Nagyszegi, L Kaizer, Z Fejes, S Hamar, E Csörgő, K Ormándi, M Lázár, G Lázár
INTRODUCTION: Intraoperative touch imprint cytology (TIC) of the sentinel lymph node(s) (SLN(s)) in the treatment of breast cancer has significantly reduced the number of axillary block dissections (ABD) required during second surgeries. Based on recent studies, ABD was not considered necessary if the presence of tumor cells/micrometastasis was confirmed in the SLN(s) or in the case of macrometastases in a patient group meeting the inclusion criteria for the ACOSOG Z0011 study. Our aim was to determine the sensitivity and usefulness of TIC with regard to these results...
January 18, 2017: European Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28056250/-outcome-evaluation-based-on-evidence-based-medicine-of-laparoscopic-surgery-for-rectal-cancer
#7
H W Yao, Y H Liu
Laparoscopic surgery of rectal cancer has experienced more than 20 years of technical development and clinical research. Based on the published high-level clinical trials such as COREAN, COLOR Ⅱ, ACOSOG Z6051 and ALacaRT, laparoscopic surgery is recommended as method to treat rectal cancer by the NCCN Clinical Practice Guideline on Rectal Cancer (version 1.2016) with class 2A evidence. But it is also suggested that the surgeons should have experiences of performing minimally invasive proctectomy with total mesorectal excision...
January 1, 2017: Zhonghua Wai Ke za Zhi [Chinese Journal of Surgery]
https://www.readbyqxmd.com/read/28045625/ki67-proliferation-index-as-a-tool-for-chemotherapy-decisions-during-and-after-neoadjuvant-aromatase-inhibitor-treatment-of-breast-cancer-results-from-the-american-college-of-surgeons-oncology-group-z1031-trial-alliance
#8
Matthew J Ellis, Vera J Suman, Jeremy Hoog, Rodrigo Goncalves, Souzan Sanati, Chad J Creighton, Katherine DeSchryver, Erika Crouch, Amy Brink, Mark Watson, Jingqin Luo, Yu Tao, Michael Barnes, Mitchell Dowsett, G Thomas Budd, Eric Winer, Paula Silverman, Laura Esserman, Lisa Carey, Cynthia X Ma, Gary Unzeitig, Timothy Pluard, Pat Whitworth, Gildy Babiera, J Michael Guenther, Zoneddy Dayao, David Ota, Marilyn Leitch, John A Olson, D Craig Allred, Kelly Hunt
Purpose To determine the pathologic complete response (pCR) rate in estrogen receptor (ER) -positive primary breast cancer triaged to chemotherapy when the protein encoded by the MKI67 gene (Ki67) level was > 10% after 2 to 4 weeks of neoadjuvant aromatase inhibitor (AI) therapy. A second objective was to examine risk of relapse using the Ki67-based Preoperative Endocrine Prognostic Index (PEPI). Methods The American College of Surgeons Oncology Group (ACOSOG) Z1031A trial enrolled postmenopausal women with stage II or III ER-positive (Allred score, 6 to 8) breast cancer whose treatment was randomly assigned to neoadjuvant AI therapy with anastrozole, exemestane, or letrozole...
April 1, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/27938572/-give-attention-to-both-minimally-invasive-surgery-and-precision-medicine-to-promote-the-scientificality-on-individualized-clinical-practice-of-rectal-cancer
#9
Y H Liu, H W Yao, L Xin
Based on the research results of COLORⅡ, COREAN, ACOSOG and ALacaRT trials, NCCN rectal cancer clinical practice guidelines (Version 1.2016) made an important update, that rectal cancer can be considered to be performed by laparoscopic method in some patients with surgical indication. The eighth edition of the TNM staging system of the AJCC will be available in 2017, in which increasing molecular biomarkers and establishing a prognostic evaluation system should be emphasized. The launch of the"cancer precision medicine"program will promote the progress on comprehensive diagnosis and treatment of rectal cancer...
June 1, 2016: Zhonghua Wai Ke za Zhi [Chinese Journal of Surgery]
https://www.readbyqxmd.com/read/27916595/the-relevance-of-ultrasound-imaging-of-suspicious-axillary-lymph-nodes-and-fine-needle-aspiration-biopsy-in-the-post-acosog-z11-era-in-early-breast-cancer
#10
Gopal R Vijayaraghavan, Srinivasan Vedantham, Milliam Kataoka, Carolynn DeBenedectis, Robert M Quinlan
RATIONALE AND OBJECTIVES: Evaluation of nodal involvement in early-stage breast cancers (T1 or T2) changed following the Z11 trial; however, not all patients meet the Z11 inclusion criteria. Hence, the relevance of ultrasound imaging of the axilla and fine-needle aspiration biopsy (FNA) in early-stage breast cancers was investigated. MATERIALS AND METHODS: In this single-center, retrospective study, 758 subjects had pathology-verified breast cancer diagnosis over a 3-year period, of which 128 subjects with T1 or T2 breast tumors had abnormal axillary lymph nodes on ultrasound, had FNA, and proceeded to axillary surgery...
March 2017: Academic Radiology
https://www.readbyqxmd.com/read/27900818/healthcare-costs-reduced-after-incorporating-the-results-of-the-american-college-of-surgeons-oncology-group-z0011-trial-into-clinical-practice
#11
Michelle M Fillion, Katherine E Glass, Joe Hayek, Allison Wehr, Gary Phillips, Alicia Terando, Doreen M Agnese
The purpose of our study was to quantitate the changes in axillary lymph node dissection (ALND), frozen section (FS), and the impact on costs after the publication of the American College of Surgeons Oncology Group (ACOSOG) Z0011 trial. We compared axillary nodal management and cost data in breast cancer patients who met Z0011 criteria and were treated with lumpectomy and sentinel lymph nodes (SLN) biopsy from 2007 to July 2013. Of 800 patients, 67 (13.5%) and 34 (12.5%) patients in the pre- and post-Z0011 era had 1-2 positive SLN...
November 30, 2016: Breast Journal
https://www.readbyqxmd.com/read/27696171/extending-acosog-z0011-to-encompass-mastectomy-what-happens-without-rt
#12
EDITORIAL
Hiram S Cody
No abstract text is available yet for this article.
September 30, 2016: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/27675634/impact-of-radiation-on-local-regional-control-in-women-with-node-positive-breast-cancer-treated-with-neoadjuvant-chemotherapy-nac-and-axillary-lymph-node-dissection-alnd-results-from-acosog-z1071-alliance
#13
B G Haffty, K V Ballman, K K Hunt, L M McCall, J C Boughey
No abstract text is available yet for this article.
October 1, 2016: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/27674369/national-practice-patterns-of-axillary-management-and-adjuvant-radiation-after-acosog-z0011
#14
J M Mann, X Wu, P Christos, D Nori, S C Formenti, H Nagar
No abstract text is available yet for this article.
October 1, 2016: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/27557827/axillary-ultrasound-for-all-for-none-to-diagnose-positive-nodes-or-to-support-avoiding-sentinel-lymph-node-biopsy-altogether
#15
Dalliah Black
Axillary ultrasound is increasingly utilized for nodal staging preoperatively in patients presenting with invasive breast cancer to provide guidance for preoperative chemotherapy or proceeding directly to surgery. Improvements in ultrasound technology make it possible to assess the nodal burden in order to identify those patients not eligible for ACOSOG Z0011 management. However, its ability to detect metastasis is variable and dependent on operator's skills, size of metastatic deposit, and primary tumor histology subtype...
January 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/27549784/one-step-nucleic-acid-amplification-osna-where-do-we-go-with-it
#16
REVIEW
Yasuhiro Tamaki
The one-step nucleic acid amplification (OSNA) assay was initially developed for the intraoperative assessment of sentinel lymph node metastases in breast cancer. This assay measures cytokeratin 19 (CK19) mRNA copy number and is widely used in hospitals. The results of the IBCSG 23-01, ACOSOG Z0011, and AMAROS trials demonstrated that no further axillary dissection is required for patients with sentinel lymph nodes that tested positive for cancer, which has led to a decreasing trend in the need for intraoperative assessment of lymph nodes...
February 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/27513155/locoregional-recurrence-after-sentinel-lymph-node-dissection-with-or-without-axillary-dissection-in-patients-with-sentinel-lymph-node-metastases-long-term-follow-up-from-the-american-college-of-surgeons-oncology-group-alliance-acosog-z0011-randomized-trial
#17
Armando E Giuliano, Karla Ballman, Linda McCall, Peter Beitsch, Pat W Whitworth, Peter Blumencranz, A Marilyn Leitch, Sukamal Saha, Monica Morrow, Kelly K Hunt
BACKGROUND AND OBJECTIVE: The early results of the American College of Surgeons Oncology Group (ACOSOG) Z0011 trial demonstrated no difference in locoregional recurrence for patients with positive sentinel lymph nodes (SLNs) randomized either to axillary lymph node dissection (ALND) or sentinel lymph node dissection (SLND) alone. We now report long-term locoregional recurrence results. METHODS: ACOSOG Z0011 prospectively examined overall survival of patients with SLN metastases undergoing breast-conserving therapy randomized to undergo ALND after SLND or no further axillary specific treatment...
September 2016: Annals of Surgery
https://www.readbyqxmd.com/read/27498412/micro-and-macro-metastasis-in-the-axillary-lymph-node-a-review
#18
REVIEW
Kalnisha Naidoo, Sarah E Pinder
Pathologists typically examine the sentinel lymph nodes excised from patients with invasive breast cancer more thoroughly than they have historically those from axillary lymph node clearance specimens. This, it is thought, increases the chances of detecting small metastatic foci (i.e. macrometastases (>2 mm), micrometastases (0.2-2 mm), or isolated tumour cell clusters (<0.2 mm or <200 cancer cells in one section)). However, the clinical significance of these small metastatic deposits remains unclear...
August 3, 2016: Surgeon: Journal of the Royal Colleges of Surgeons of Edinburgh and Ireland
https://www.readbyqxmd.com/read/27479042/the-impact-of-the-american-college-of-surgeons-oncology-group-acosog-z0011-trial-an-institutional-review
#19
Viet H Le, Kathleen N Brant, Dawn W Blackhurst, Christine M G Schammel, David P Schammel, Wendy R Cornett, Brian P McKinley
BACKGROUND: Axillary dissection (AD) was historically recommended for all patients with breast tumor involvement discovered by sentinel lymph node biopsy (+SLNB). However, after the ACOSOG Z0011 trial, omission of AD became the recommendation for selected patients with a +SLNB. We report the impact of ACOSOG Z0011 on the completion AD rate in patients with +SLNB at our institution. METHODS: We retrospectively reviewed all patients diagnosed with breast cancer between March 2009 and February 2013 (n = 1781)...
October 2016: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/27449492/impact-of-race-ethnicity-and-bmi-on-achievement-of-pathologic-complete-response-following-neoadjuvant-chemotherapy-for-breast-cancer-a-pooled-analysis-of-four-prospective-alliance-clinical-trials-a151426
#20
Erica T Warner, Karla V Ballman, Carrie Strand, Judy C Boughey, Aman U Buzdar, Lisa A Carey, William M Sikov, Ann H Partridge
Previous studies demonstrated poor response to neoadjuvant systemic therapy (NST) for breast cancer among black women and women who are overweight or obese, but this may be due to chemotherapy underdosing. We assessed associations of race, ethnicity, and body mass index (BMI) with pathologic complete response (pCR) in clinical trial populations. 1797 women enrolled in four NST trials (CALGB 40601, 40603; ACOSOG Z1041, Z1071) were included. Tumor subtypes were defined by estrogen receptor (ER) and HER2 status...
August 2016: Breast Cancer Research and Treatment
keyword
keyword
13249
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"